A New Chapter in Precision Medicine: Announcing Amplitude’s Second Fund
We are pleased to celebrate the milestone of closing our second Precision Medicine fund . As in all things, this was a true team effort from everyone at Amplitude. We’re grateful to our Fund I and Fund II investors and our CEOs — all of whom provided support, referrals and answered tons of reference calls from new LPs. We are fortunate to have built deep and long-standing relationships with our core investors — the same ones who supported us from our launch. They have provided valuable feedback on strategy, fund size and stepped forward with strong and early commitments.
We are also grateful for the commitments that the Federal and Provincial governments are making to support the innovation community through the VCCI program and the provincial governments of Quebec, Ontario, British Columbia and Alberta for recognizing that translating innovation from the lab to the patient requires a concentration of capital and company-building investors to build world-leading companies that can go from idea to IPO.
In this fundraise, we sought out new partners that could accelerate company development by bringing key insights, infrastructure and talent to our company creation process, which has culminated in our venture studio. Pre-Amp is now a high-functioning company generator. Adding key global partners like Evotec to our team provides a new competitive edge and allows us to focus on highly original ideas.
We are inspired by our engagement with the innovation community and believe that this is a very opportune time in the market to deploy capital. We are increasingly focusing our investing efforts on unlocking the potential of digital technologies applied to biological problems — the intersection of AI/ML with biology and believe that successful future companies will require the skills of a multi-disciplinary team — a biologist, chemist, engineer and computer scientist.
We believe this digital revolution of life sciences is transforming all stages of development from the beginning stages of understanding biological systems, the process of validation, modality development, clinical development, regulatory approval, and ultimately to manufacturing and commercialization. It is more appropriate to think of the modern lab as a data factory with increased robotics deploying samples across data-rich chips, using tools like Cryo-EM, or leveraging predictive libraries of protein structure like AlphaFold.
We believe this is a great time to be investing new capital into the sector. After the over-inflated financing environment of 2020–22, the venture market has settled back in line with long-term trends, enabling us to work more closely with entrepreneurs to think strategically about how to build great companies without the pressures of having to drive to a rapid exit. We are investing more of our team’s time at the early stages of the investing cycle to support innovation translation and think broadly about how to build the strong foundation that a company needs to be successful.
-The Amplitude Team
***
About Amplitude
Amplitude Ventures is a full-stack venture capital firm using a unique growth model to build companies with world-class management teams and to scale companies to breakout potential. With more than $500 million in assets under management and offices in Montreal, Toronto, and Vancouver, Amplitude applies a proven, evidence-based approach to investing in leading precision medicine companies. Visit amplitudevc.com to learn more.
A New Chapter in Precision Medicine: Announcing Amplitude’s Second Fund was originally published in Amplitude VC on Medium, where people are continuing the conversation by highlighting and responding to this story.
Full content in Amplitude Ventures
